482 related articles for article (PubMed ID: 34609596)
41. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
42. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
43. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
44. Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair.
Gao J; Pang Z; Wang Q; Tan Y; Li Q; Tan H; Chen J; Yakufu W; Wang Z; Yang H; Zhang J; Sun D; Weng X; Wang Q; Qian J; Song Y; Huang Z; Ge J
Adv Sci (Weinh); 2024 Jun; 11(24):e2306388. PubMed ID: 38477522
[TBL] [Abstract][Full Text] [Related]
45. Role of CD47 in Hematological Malignancies.
Eladl E; Tremblay-LeMay R; Rastgoo N; Musani R; Chen W; Liu A; Chang H
J Hematol Oncol; 2020 Jul; 13(1):96. PubMed ID: 32677994
[TBL] [Abstract][Full Text] [Related]
46. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
[TBL] [Abstract][Full Text] [Related]
47. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
[TBL] [Abstract][Full Text] [Related]
48. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
Andrejeva G; Capoccia BJ; Hiebsch RR; Donio MJ; Darwech IM; Puro RJ; Pereira DS
J Immunol; 2021 Feb; 206(4):712-721. PubMed ID: 33431660
[TBL] [Abstract][Full Text] [Related]
49. RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia.
Oronsky B; Cabrales P; Caroen S; Guo X; Scribner C; Oronsky A; Reid TR
Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):355-357. PubMed ID: 33432831
[No Abstract] [Full Text] [Related]
50. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
Wang Y; Ni H; Zhou S; He K; Gao Y; Wu W; Wu M; Wu Z; Qiu X; Zhou Y; Chen B; Pan D; Huang C; Li M; Bian Y; Yang M; Miao L; Liu J
Cancer Immunol Immunother; 2021 Feb; 70(2):365-376. PubMed ID: 32761423
[TBL] [Abstract][Full Text] [Related]
51. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
He Y; Helfrich W; Bremer E
Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
[TBL] [Abstract][Full Text] [Related]
52. Just eat it: A review of CD47 and SIRP-α antagonism.
Oronsky B; Carter C; Reid T; Brinkhaus F; Knox SJ
Semin Oncol; 2020; 47(2-3):117-124. PubMed ID: 32517874
[TBL] [Abstract][Full Text] [Related]
53. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
54. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
[TBL] [Abstract][Full Text] [Related]
55. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D
J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270
[TBL] [Abstract][Full Text] [Related]
56. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
[TBL] [Abstract][Full Text] [Related]
57. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
Front Immunol; 2020; 11():593219. PubMed ID: 33329583
[TBL] [Abstract][Full Text] [Related]
58. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
59. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
Swoboda DM; Sallman DA
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
[TBL] [Abstract][Full Text] [Related]
60. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]